Boston Scientific stock in focus after slower Q3 growth

Published on 10/30/2026 at 11:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Boston Scientific stock is in focus after third-quarter growth slowed to 1.5 percent. Management highlighted operational resilience and its innovation pipeline.

Boston Scientific reports slower third-quarter growth

Third-quarter net sales reached 5.138 billion US dollars, rising 1.5 percent from the prior-year period.
Organic growth was 0.7 percent in MedSurg and 1.9 percent in Cardiovascular.
Management highlighted the response to the August cybersecurity incident and pointed to the company's long-term innovation strategy.

Boston Scientific, US1011371077, Illustration mit AI erstellt.

Boston Scientific reported its third-quarter 2026 results on Wednesday, October 28, with net sales of 5.138 billion US dollars, up 1.5 percent from the year-earlier period. The company said the increase was recorded on a reported and organic basis in its official earnings update.

Boston Scientific stock traded at 38.09 euros on Lang & Schwarz at 11:02 CET on Friday, October 30, 2026. The quote provides the current market indication without a further daily direction in this report.

Growth differs across business lines

All reportable segments delivered sales growth in the quarter, but the pace varied. MedSurg posted organic growth of 0.7 percent, while Cardiovascular grew 1.9 percent organically. The figures show continued expansion across the portfolio, although overall growth was modest compared with the company's broader long-term ambitions.

Boston Scientific described the year as challenging and said its global teams had responded to the cybersecurity incident reported in August. Chief Executive Officer Mike Mahoney emphasized the restoration of operations, customer and patient support, and confidence in the company's long-term strategy.

The company also pointed to product and portfolio developments during the quarter. The US Food and Drug Administration cleared two technologies in the StoneSmart Solutions ecosystem and expanded the available sizes for the SEISMIQ intravascular lithotripsy peripheral catheter. Boston Scientific also reported new reimbursement codes for renal denervation and implantable tibial nerve stimulation devices that are scheduled to take effect in January 2028.

Portfolio investments remain central

Boston Scientific entered a strategic collaboration with Heartflow to advance artificial-intelligence-supported, computed-tomography-guided planning for percutaneous coronary intervention. The cooperation links Heartflow's PCI Navigator tool with Boston Scientific's AVVIGO+ Multi-Modality Guidance System and underlines management's focus on procedure planning and differentiated technology.

The company's official Q3 2026 earnings update said that the outlook includes expectations for fourth-quarter and full-year sales, adjusted earnings per share and the effects of the August cybersecurity incident. Investors will therefore focus next on the company's detailed financial release and management commentary on the pace of recovery.

For the latest trading indication, investors can follow the real-time quote of Boston Scientific stock.

The broader US market context is covered in current S&P 500 market reports.

More news and analyses on Boston Scientific stock